MedTrace Logo

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

NCT01232127 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2012-08-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effects of famotidine, given twice daily, on atazanavir administered with ritonavir and tenofovir in HIV-infected participants.

Conditions

Interventions

DRUG

Atazanavir

Capsule, oral, 300 mg, once daily, 10 days

DRUG

Atazanavir

Capsule, oral, 400 mg, once daily, 7 days

DRUG

Ritonavir

Capsule, oral, 100 mg, once daily, 10 days

DRUG

Ritonavir

Capsule, oral, 100 mg, once daily, 7 days

DRUG

Tenofovir (TDF)

Capsule, oral, 300 mg, once daily, 10 days

DRUG

Tenofovir (TDF)

Capsule, oral, 300 mg, once daily, 7 days

DRUG

Nucleoside Reverse Transcriptase Inhibitor (NRTI)

Oral, 10 days

DRUG

Nucleoside Reverse Transcriptase Inhibitor (NRTI)

Oral, 7 days

DRUG

Famotidine (FAM)

Tablet, oral, 20 mg, twice daily, 7 days

DRUG

Famotidine (FAM)

Tablet, oral, 40 mg, twice daily, 7 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01232127 on ClinicalTrials.gov